The contribution of classical (β( 1/4 )-) and atypical β-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel β3-adrenoceptor agonists of differing selectivities

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1084-1095

  Sennitt, Matthew V ^b,e   Kaumann, Alberto J ^c,d   Molenaar, Peter ^d   Beeley, Lee J ^a   Young, Paul W ^a   Kelly, John ^a   Chapman, Helen ^a   Henson, Sian M ^a   Berge, John M ^a   Dean, David K ^a   Kotecha, Nikesh R ^a   Morgan, Helen K A ^a   Rami, Harshad K ^a   Ward, Robert W ^a   Thompson, Mervyn ^a   Wilson, Shelagh ^a   Smith, Stephen A ^a   Cawthorne, Michael A ^e   Stock, Michael J ^b   Arch, Jonathan R S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c BABRAHAM INSTITUTE   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF BUCKINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ARYLOXYPROPANOLAMINE; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; CYCLOHEXYL[4 [2 [2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYLAMINO]ETHYL]PHENOXYMETHYL]PHOSPHINIC ACID; ISOPRENALINE; PHENYLETHANOLAMINE; SB 215691; SB 220646; SB 229432; SB 236923; SB 246982; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG ACTIVITY; DRUG SELECTIVITY; HEART ATRIUM CONTRACTION; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; STEREOCHEMISTRY; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HAMSTER; HEART ATRIUM FUNCTION; HUMAN; LIPOLYSIS; MALE; MIDDLE AGED; PHYSIOLOGY;

ADIPOSE TISSUE; ADRENERGIC BETA-AGONISTS; ANIMALS; ATRIAL FUNCTION, RIGHT; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; HUMANS; LIPOLYSIS; MALE; MIDDLE AGED; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA;

EID: 7144254440     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. 3-adrenoceptors in tissues. Pharmacol Commun 1-3:223-228.
2. 3-adrenoceptors and other putative atypical β-adrenoceptors. Pharmacol Rev Commun 9:141-148.
3. 3 and atypical β-adrenoceptors. Med Res Rev 13: 6.663-729.
4. 3-Adrenoceptors and the regulation of metabolism in adipose tissues. Biochem Soc Trans 24:412-418.
5. Beeley LJ, Berge JM, Chapman H, Dean DK, Kelley J, Lowden L, Kotecha NR, Morgan HKA, Rami HK, Thompson M, Vong AKK and Ward RW (1997) A simplified template approach towards the synthesis of a potent beta-3 adrenoceptor agonist at the human receptor. Bioorg Med Chem 7:2.219-224.
6. 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289:223-228.
7. Blinks JR (1965) Convenient apparatus for recording contractions of isolated muscle J Appl Physiol 20:755-757.
8. Boobis LH and Maughan RJ (1983) A simple one step fluorimetric method for the determination of glycerol in 20 μl of plasma. Clin Chem Acta 132:178-179.
9. 3-adrenoceptor refractory to down-regulation. Biochem J 303:973-978.
10. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. 3-selective adrenoceptor antagonist SR 59230A. Br J Pharmacol 117:1374-1376.
12. 3-adrenoceptors in human brown and white adipose tissues. Br J Pharmacol 118:929-934.
13. 3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci 15:3-7.
14. 3-Adrenoceptor in the human heart. J Clin Invest 98:2.556-562.
15. 2+] uptake by human platelets. Platelets 2:93-98.
16. 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn-Schmiedeberg Arch Pharmacol 331:60-70.
17. S. Mol Pharmacol 41:889-893.
18. 3-adrenoceptor in rat ileum. Br J Pharmacol 119: 564-568.
19. 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obesity 20:428-434.
20. Hollenga C, Brouwer F and Zaagsma J (1991) Differences in functional cyclic AMP compartments mediating lipolysis by isoprenaline and BRL 37344 in four adipocyte types. Eur J Pharmacol 200:325-330.
21. Kaumann AJ (1996) (-)-CGP 12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br J Pharmacol 117:93-98.
22. Kaumann AJ (1997) Four β-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 18:70-76.
23. 3-adrenoceptor in the rat. Br J Pharmacol 118:2085-2098.
24. Kaumann AJ and Molenaar P (1997) Modulation of human cardiac function through four β-adrenoceptor populations. Naunyn-Schmiedeberg Arch Pharmacol 355:667-681.
25. 3-adrenoceptor in human isolated taenia coli. Br J Pharmacol 120:207P.
26. Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
27. Kenakin T (1997) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
28. 3-adrenergic receptor mRNA in man. J Clin Invest 91:344-349.
29. Langin D, Portillo MP, Saulnier-Blache J and Lafontan M (1991) Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199:291-301.
30. 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42:634-637.
31. Liu Y-L, Cawthorne MA and Stock MJ (1996) Biphasic effects of the β-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle. Br J Pharmacol 117:1355-1361.
32. 3-adrenoceptor in man. Br J Pharmacol. 110:929-936.
33. Maclaughlin DP and Macdonald A (1991) Characterization of catecholaminemediated relaxations in rat isolated gastric fundus: evidence for an atypical β-adrenoceptor. Br J Pharmacol 103:1351-1356.
34. 4-Adrenoceptor' in mammalian heart. Clin Exp Pharmacol Physiol 24:647-656.
35. 1-adrenergic receptors. J Recept Signal Transduct Res 16:1-2.1-23.
36. Portillo MP, Rocandio AM, Garciacalonge MA, Diaz E, Campo E, Martinezblazquez C, Errasti J and Delbarrio AS (1995) Lipolytic effects of beta(1), beta(2) and beta(3)-adrenergic agonists in isolated human fat-cells from omental and retroperitoneal adipose tissues. Rev Espanola Fisiol 51:4.193-200.
37. 3-adrenergic receptor in human white adipose tissue. J Mol Endocrinol 10:193-197.
38. 3-adrenergic effect on lipolysis in human subcutaneous adipose tissue. J Clin Endocrinol Metab 77:2.352-355.
39. Salomon Y, Londos C and Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
40. 3-adrenoceptor using CGP 12177. Int J Obesity 18:Suppl 2.19.
41. Tate T, Briend-Sutren M, Emorine LJ, Delavier-Klutchko C, Marullo S and Strosberg AD (1991) Expression of three human β-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells. Eur J Biochem 196:357-361.
42. 3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. J Lipid Res 37:1.87-97.
43. 3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human. Mol Pharmacol 43: 343-348.
44. Van Liefde I, Van Ermen A and Vauquelin G (1994) No functional atypical β-adrenergic receptors in human omental adipocytes. Life Sci 54:12.209-214.
45. Wang T, Kaumann AJ and Brown MJ (1996) (-)-Timolol is a more potent antagonist of the positive inotropic effects of (-)-adrenaline than of those of (-)-noradrenaline in human atrium. Br J Clin Pharmacol 42:217-223.
46. 3-adrenoceptor depends on receptor expression level and nature of the assay. J Pharmacol Exp Ther 279:214-221.